Stage III Invasive Lobular Carcinoma: Betsy's Patient Story

Patient Info: Betsy | Stage III

Betsy continues long-term hormone therapy with anastrozole after almost 2 years of tamoxifen.

Lobular Breast Cancer AllianceRead more →

BRCA2 Breast Cancer: Erika's Patient Story

Patient Info: Erika, Female, Under 40

Biomarkers: BRCA2 mutation

As of June 2026, Erika had no cancer diagnosis after a BRCA2-positive result and preventive double mastectomy with implant reconstruction, with ongoing hereditary-risk surveillance.

The Patient StoryRead more →

Stage I Invasive Ductal Carcinoma: Rachel's Patient Story

Patient Info: Rachel, Female | Stage I

Biomarkers: Genetic testing inconclusive; receptor status not reported

As of June 2026, Rachel had completed double mastectomy and chemotherapy for Stage IB breast cancer and remained on planned 10-year tamoxifen therapy, with ongoing joint/muscle pain, weight gain, and survivorship effects.

The Patient StoryRead more →

Stage I HR-Positive Invasive Ductal Carcinoma: Amelia's Patient Story

Patient Info: Amelia, Female, 40s | Stage I

Biomarkers: ER-positive; PR-positive; HER2-negative; BRCA negative; Oncotype DX score 22

As of June 2026, Amelia had no evidence of disease after lumpectomy, bilateral mastectomy, TC chemotherapy, and reconstruction, and she remained on tamoxifen.

The Patient StoryRead more →

Stage II HR-Positive Invasive Ductal Carcinoma: Cat's Survivor Story

Patient Info: Cat, Female | Stage II

Biomarkers: ER-positive; Oncotype recurrence risk discussed

As of June 2026, Cat described being cancer-free after bilateral mastectomy, 4 months of chemotherapy, reconstruction, and a period on tamoxifen for ER-positive Stage IIB breast cancer.

The Patient StoryRead more →

Stage 0 HR-Positive Invasive Ductal Carcinoma: Natalie's Survivor Story

Patient Info: Natalie, Female | Stage 0

Biomarkers: ER-positive

As of June 2026, Natalie was living after Stage 0 DCIS, later nipple/Paget's disease recurrence, and 20 surgeries through May 2019, with a full life and ongoing attention to physical changes after reconstruction.

The Patient StoryRead more →

Stage III HR-Positive Invasive Lobular Carcinoma: Tina's Patient Story

Patient Info: Tina, Female, Under 40 | Stage III

Biomarkers: ER-positive

As of June 2026, Tina was in survivorship after double mastectomy, AC-T chemotherapy, radiation, and ongoing hormone therapy with daily tamoxifen and Zoladex every 3 months.

The Patient StoryRead more →

Metastatic triple-negative breast cancer with orbital and bone metastases responding to nab-paclitaxel plus everolimus

Patient Info: Anonymized, Female, 70+ | Stage IV

Biomarkers: Primary breast cancer was ER-low, PR/HER2 negative. Orbital metastasis was triple-negative with AKT1 exon 4 mutation.

Metastatic Site: right orbit/orbital mass; bone

At 6-month follow-up, systemic disease was stable, ocular symptoms had significantly improved, orbital metastases were stable on MRI, and the response was described as RECIST partial response/progression-free interval while treatment continued.

PubMed CentralRead more →

Breast cancer treatment during pregnancy followed by postpartum targeted therapy

Patient Info: Anonymized, Female, Under 40 | Stage IV

She achieved a near-complete response after 4 cycles of docetaxel and then continued systemic treatment after delivery.

PubMed CentralRead more →

Stage IV HR-Positive Breast Cancer: Joelle's Patient Story

Patient Info: Joelle, Female, Under 40 | Stage IV

Biomarkers: HR-positive / hormone-positive

Metastatic Site: Bone/hip; lymph nodes; other sites not specified

Living with Stage IV hormone-positive breast cancer on ongoing systemic therapy and monitoring, with tumor-marker checks every 3 months and scans every 6 months; no remission or NED status is stated.

The Patient StoryRead more →

Hormone receptor-positive high-grade encapsulated papillary breast carcinoma with limited invasion

Patient Info: Anonymized, Female, 40s

Biomarkers: ER/PR-positive, HER2-negative breast cancer; Ki-67 high in papillary/high-grade invasive areas; sentinel lymph nodes negative.

After mastectomy, sentinel-node evaluation, S-1, and endocrine therapy, she remained disease-free and in good health under regular follow-up.

PubMed CentralRead more →

Metastatic invasive lobular breast cancer with stomach, ovarian, peritoneal, rectal, and jejunal spread

Patient Info: Anonymized, Female, 40s | Stage IV

Biomarkers: Primary tumor and gastric metastasis were ER/PR positive and HER2 negative; GATA3 supported breast origin in the metastasis.

Metastatic Site: stomach; ovaries; peritoneum; rectum; jejunum

During 2025, she remained under active oncologic management for metastatic invasive lobular breast cancer with gastrointestinal, ovarian, peritoneal, rectal, and jejunal involvement.

PubMed CentralRead more →

Metastatic Breast Cancer Treatment After Abemaciclib-Related Liver Injury — Case 4

Patient Info: Anonymized, female, 50s | Stage IV

After recovery from abemaciclib-related liver injury, palbociclib treatment continued without recurrent liver dysfunction.

PubMed CentralRead more →

Stage IV ER/PR-positive breast cancer with retinal vein and artery occlusion during endocrine-targeted therapy

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: ER 70%; PR 100%; HER2-negative; Ki-67 10%

Metastatic Site: bone (cranial vault, right first rib, sternum, D5, D6,…

As of November 2025, she continued care for Stage IV ER/PR-positive breast cancer with bone metastases while also managing severe left-eye retinal vascular occlusion and limited visual recovery.

PubMed CentralRead more →

Recurrent breast cancer complicated by T-DXd-associated dermatomyositis and interstitial lung disease

Patient Info: Anonymized, Female, 40s | Stage III

Biomarkers: Initial tumor had weak ER/AR, PR-negative, HER2 0. Recurrence became ER/PR/AR-negative, HER2-low, PD-L1 CPS ~30.

The cancer progressed after adjuvant therapy and again after 6 cycles of gemcitabine/carboplatin. Trastuzumab deruxtecan was followed by dermatomyositis features and interstitial pneumonia, with symptoms worsening despite glucocorticoid treatment after continued exposure.

PubMed CentralRead more →

HER2-positive DCIS with KLHL11 encephalitis and pulmonary adenocarcinoma in situ

Patient Info: Anonymized, Female, Under 40 | Stage 0

Biomarkers: Breast DCIS was ER/PR positive and HER2 positive

After local breast treatment and later lung resection, she was asymptomatic on levetiracetam and tamoxifen, with no recurrent fever, seizures, or ataxia reported.

PubMed CentralRead more →

Stage IIIC ER-positive male breast cancer: mastectomy, chemotherapy, radiation, tamoxifen and abemaciclib

Patient Info: Anonymized, Male, 40s | Stage III

Biomarkers: ER 90% positive; PR 60% positive; HER2 score 0; Ki-67 15%; BRCA1 and BRCA2 no pathogenic variants; CEA 2.4 ng/mL; CA15-3 13.6 U/mL

He remained on tamoxifen and dose-adjusted abemaciclib; annual follow-up imaging, including non-contrast CT, showed no local or distant relapse.

PubMed CentralRead more →

Stage IIA ER/PR-positive mucinous breast cancer: tamoxifen plus cryoablation with no recurrence

Patient Info: Anonymized, Female, 70+ | Stage II

Biomarkers: ER/PR strongly positive, HER2 negative; CA15-3 and CEA remained normal during follow-up.

At approximately 32 months after cryoablation, the treated area had decreased to a less distinct 0.7 cm scar-like region, with no evidence of recurrence in either breast, axillae, or distant sites.

PubMed CentralRead more →

Stage I ER-positive PR-negative breast cancer: disease-free after lumpectomy, radiation and tamoxifen

Patient Info: Anonymized, Female, 40s | Stage I

Biomarkers: ER 2+ in 60% of tumor cells; PR-negative; HER2/neu-negative; Ki-67 5%; 0/6 lymph nodes positive

At 15 months after surgery, she was disease-free, had no complaints, and was satisfied with the surgical result.

PubMed CentralRead more →

ER/PR/HER2-positive breast cancer: gallbladder, liver, lung, pleural, and bone metastases after incomplete adjuvant therapy

Patient Info: Anonymized, Female, 40s | Stage IV

Biomarkers: Triple-positive breast cancer. Gallbladder metastasis kept ER/PR/HER2 positivity and Ki-67 >40%; markers supported breast origin.

Metastatic Site: gallbladder, liver, lung/pleura, bone

The patient died 3 years and 10 months after lumpectomy after metastatic ER/PR/HER2-positive breast cancer involved the gallbladder, liver, lungs/pleura, and bones following incomplete adjuvant therapy and loss to surveillance.

PubMed CentralRead more →

Stage IV Invasive Lobular Carcinoma: Nikoo's Patient Story

Patient Info: Nikoo, Female, 40s | Stage IV

Biomarkers: BRCA1/2 negative; PIK3 mutation reported on liquid biopsy

Metastatic Site: Peritoneal/abdominal lining; abdominal lymph nodes

Nikoo had Stage I invasive lobular breast cancer in 2003 and developed Stage IV metastatic recurrence in 2022 after about 19 years. As of October 2025, she was living with metastatic lobular breast cancer, had moved through multiple systemic options, and was participating in a Phase 1 clinical trial.

The Patient StoryRead more →

Breast Cancer: Theresa's Survivor Story

Patient Info: Theresa, Female, 40s

Biomarkers: Hormone receptor-positive; exact receptors not fully specified

Theresa completed treatment for multiple cancers, including bilateral mastectomy/reconstruction for breast cancer and later excision plus 3 months of radiation for chest-wall recurrence. As of October 2025, she described being about 6 years out from the later recurrence, with no other cancer found on scans.

The Patient StoryRead more →

Hormone receptor-positive male breast cancer: spontaneous regression after biopsy and mastectomy

Patient Info: Anonymized, Male, 50s

Biomarkers: ER-positive; PR-positive; HER2-negative; p63 staining confirmed myoepithelial cells in residual benign cystic lesion

Mastectomy and axillary clearance showed no residual invasive carcinoma or carcinoma in situ, with clear margins; he recovered well and began adjuvant tamoxifen because of the original ER/PR-positive biopsy.

PubMed CentralRead more →

Stage 0 ER-positive DCIS: mastectomy without adjuvant therapy, followed by successful pregnancy

Patient Info: Anonymized, Female, 40s | Stage 0

Biomarkers: ER-positive; PgR-positive; HER2-negative; nuclear grade 2; comedo type; negative margins; no lymph node involvement

She completed surgical treatment for Stage 0 DCIS with negative margins and no lymph node involvement, avoided adjuvant therapy, resumed assisted reproductive treatment, and delivered a healthy male infant.

PubMed CentralRead more →